SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Prothena Corporation
May. 17, 2018
NEW YORK--(BUSINESS WIRE)--May 17, 2018--Levi & Korsinsky announces it has commenced an investigation of Prothena Corporation (“Prothena” or “the Company”) (NASDAQGS: PRTA) concerning possible violations of federal securities laws.
On October 15, 2015, Prothena announced its late-stage Phase 2b “PRONTO” study and expansion of its Phase 1/2 clinical trial for the antibody NEOD001. On April 23, 2018, Prothena announced it was ending development of NEOD001 after its Phase 2b PRONTO trial failed to reach either its primary or secondary endpoints. Following this news, shares of Prothena fell from a close of $36.84 on April 20, 2018, to a close of $11.50 per share on April 23, 2018. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180517005971/en/
CONTACT: Levi & Korsinsky, LLP
Eduard Korsinsky, Esq., 212-363-7500
Toll Free: 877-363-5972
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK
INDUSTRY KEYWORD: PROFESSIONAL SERVICES LEGAL
SOURCE: Levi & Korsinsky, LLP
Copyright Business Wire 2018.
PUB: 05/17/2018 11:11 AM/DISC: 05/17/2018 11:11 AM